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Background: The transcription factor Ets1 is highly expressed in B lymphocytes. Loss 
of Ets1 leads to premature B  cell differentiation into antibody-secreting cells (ASCs), 
secretion of autoantibodies, and development of autoimmune disease. Despite the 
importance of Ets1 in B cell biology, few Ets1 target genes are known in these cells.
results: To obtain a more complete picture of the function of Ets1 in regulating 
B cell differentiation, we performed Ets1 ChIP-seq in primary mouse B cells to identify 
>10,000-binding sites, many of which were localized near genes that play important 
roles in B cell activation and differentiation. Although Ets1 bound to many sites in the 
genome, it was required for regulation of less than 5% of them as evidenced by gene 
expression changes in B cells lacking Ets1. The cohort of genes whose expression was 
altered included numerous genes that have been associated with autoimmune disease 
susceptibility. We focused our attention on four such Ets1 target genes Ptpn22, Stat4, 
Egr1, and Prdm1 to assess how they might contribute to Ets1 function in limiting ASC 
formation. We found that dysregulation of these particular targets cannot explain altered 
ASC differentiation in the absence of Ets1.
conclusion: We have identified genome-wide binding targets for Ets1 in B cells and 
determined that a relatively small number of these putative target genes require Ets1 for 
their normal expression. Interestingly, a cohort of genes associated with autoimmune 
disease susceptibility is among those that are regulated by Ets1. Identification of the 
target genes of Ets1 in B cells will help provide a clearer picture of how Ets1 regulates 
B cell responses and how its loss promotes autoantibody secretion.
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inTrODUcTiOn
B cells are crucial contributors to immunity both by secreting specific antibodies and by serving as 
antigen-presenting cells. B  cell immune responses and differentiation to antibody-secreting cells 
(ASCs) are controlled by the expression and activation of specific transcription factors at different 
stages and time points in B cell development and functional activation. For instance, the transcription 
Abbreviations: ASCs, antibody-secreting cells; BCR, B cell receptor; ChIP-seq, chromatin immunoprecipitation-sequencing; 
ENCODE, encyclopedia of DNA elements; FPKM, fragments per kilobase of transcript per million mapped reads; GO, gene 
ontology; GWAS, genome-wide association study; IRES, internal ribosomal entry site; LPS, lipopolysaccharide; SNPs, single-
nucleotide polymorphisms; ShRNA, short hairpin RNA.
2Saelee et al. Ets1 Regulates Autoimmune-Associated Genes
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 383
factors Pax5, Ebf1, E2a (Tcf3), and Foxo1 are required for the 
development of B  cell progenitors in the bone marrow and in 
mature and peripheral B cells (1–7). A different set of transcription 
factors including Blimp1 (Prdm1), Xbp1, and Irf4 are required 
for B  cells to undergo ASC differentiation. Blimp1 stimulates 
immunoglobulin secretion and suppresses mature B  cell gene 
expression (8, 9). Xbp1 is required for endoplasmic reticulum 
remodeling and high-level immunoglobulin production (10, 11). 
Irf4 is also required for ASC differentiation (12), although the 
mechanisms by which it does so are still under debate (13).
In addition to the transcription factors summarized above, 
various members of the Ets gene family also regulate B cell dif-
ferentiation and function. The roles of six Ets proteins have been 
studied in detail in B lymphocytes, including Ets1 (14), Fli1 (15, 
16), Gabpa (17), and the three related Ets family factors PU.1, 
SpiB, and SpiC (18, 19). Two additional Ets proteins, Elf3 (Ese1) 
and Elf4 (MEF) have been reported to affect B cell development 
or functional responses (20, 21), although their detailed roles in 
this process have not yet been identified.
Ets1, the prototypical member of the Ets gene family, is highly 
expressed in B cells and is necessary for maintaining them in a 
quiescent state, since lack of Ets1 leads to premature differentia-
tion into ASCs (22, 23). This is accompanied by a loss of B cell 
tolerance to self-antigens (24). Ets1−/− mice also lack marginal 
zone type B cells, possibly because of depletion due to excessive 
differentiation to ASCs (23, 25). In keeping with a role for Ets1 in 
establishing B cell tolerance, Ets1−/− mice develop an autoimmune 
phenotype (23, 26) and single-nucleotide polymorphisms (SNPs) 
in the human ETS1 gene have been highly implicated in a variety 
of autoimmune diseases (27, 28).
The most well-studied function of Ets1 in B cells is in regulating 
the formation of ASCs. One mechanism by which Ets1 regulates 
this process is by forming a protein–protein complex with Blimp1 
resulting in the inhibition of Blimp1 DNA binding (22, 29). 
Ets1 may also regulate B  cell differentiation through direct 
binding to target genes. To date, only a few such target genes 
of Ets1 have been identified in B  cells, including Pax5 (22, 
29–37), which is crucial for maintaining mature B cell identity. 
In our study, we identify Ets1-binding sites in mouse B  cells 
using ChIP-sequencing and identify gene expression changes in 
the absence of Ets1 using RNA-sequencing. Interestingly, many 
of these target genes are implicated in autoimmune responses, 
a cohort of which is tested for their ability to restore normal 
differentiation to Ets1−/− B  cells. Restoring the normal expres-
sion levels of four of these Ets1 targets (Stat4, Ptpn22, Egr1 and 
Prdm1) failed to reverse the Ets1−/− B cell phenotype of excessive 
plasma cell differentiation in response to TLR ligands. Instead, 
restoring Stat4 and Ptpn22 resulted in increased plasma cell 
differentiation. Therefore, other targets of Ets1 or the combined 
actions of multiple targets may be crucial for regulating this 
B cell differentiation step.
MaTerials anD MeThODs
Mice
Wild-type (WT) C57BL/6 mice were purchased from Jackson 
Laboratory. Ets1−/− mice (RRID:MGI: 3833458) and littermate 
WT controls used in this study were bred in our facility and 
maintained on a mixed genetic background of C57BL/6 × 129Sv 
because, on a pure C57BL/6 genetic background, the loss of 
Ets1 is lethal perinatally. The mutation in the Ets1 locus of these 
mice has previously been described (23, 38). Mice carrying 
the Prdm1-green fluorescent protein (GFP) allele that inac-
tivates Blimp1 were obtained from Dr. Stephen Nutt (Walter 
and Eliza Hall Institute of Medical Research, Parkville, VIC, 
Australia) (39).
B cell Purification and chiP-seq
Wild-type mouse B cells were purified from spleens of 3-month-
old C57BL/6 male mice using negative selection with the Easysep 
mouse B  cell isolation kit (Stem Cell Technologies). Purified 
B cells were rested for 1 h in complete media [RPMI 1640 + 10% 
fetal bovine serum, 1% pen/strep, 1% Glutamax (Gibco), and 
50  µM β-mercaptoethanol] in a tissue culture incubator. After 
resting, cells were cross-linked by adding formaldehyde to a final 
concentration of 0.25% for 8 min. Fixed B cells were lysed and 
chromatin prepared according to the manufacturer’s protocol for 
the ChIP-IT High Sensitivity Kit (Active Motif). Chromatin was 
sonicated to yield fragments of an average size ~200–700 bp and 
immunoprecipitated with a rabbit polyclonal anti-Ets1 antibody 
(sc-350X, Santa Cruz) that has previously been used in chromatin 
immunoprecipitation assays (40–42). Two biological replicates 
were separately prepared and analyzed. The number of uniquely 
mapped reads for ChIP-seq was between 10 and 27 million for 
the Ets1 ChIP-seq and between 7 and 10 million for sequencing 
of the input.
Libraries were generated from the purified chromatin, and 
ChIP-sequencing was performed on input chromatin and Ets1-
precipitated chromatin using an Illumina Hiseq2500 Sequencing 
System. The ChIP-seq data were found to be of good quality 
using the normalized strand coefficient and the relative strand 
correlation parameters as described previously (43). The reads 
were aligned to mouse mm9 genome assembly using Bowtie (44).
Bioinformatics analyses of chiP-seq
We identified Ets1-bound regions using the MACS2 program 
(45). Peaks identified from each biological replicate were 
compared to input controls using the irreproducible discovery 
rate to identify reproducible Ets1-binding sites of which 10,391 
were detected. Ets1-bound regions were annotated for enrich-
ment at intergenic regions, promoters, exons, or introns using 
ChIPseeker (46). Overrepresented motifs in the peaks were 
analyzed using the findmotifgenome function in Homer (47). 
Locations of binding sites with respect to potential target genes 
were visualized in GenomeBrowser (https://genome.ucsc.edu/
cgi-bin/hgGateway).
Ets1 consensus binding sites and other transcription factor-
binding sites in the Ets1-bound regions were identified using 
PscanChIP (48). The regions were then aligned centered on the 
Ets1 consensus motif. ChIP-seq data for acetylated and methyl-
ated lysine variants of histone H3 in primary B cells were obtained 
from the GEO database and are reported in Ref. (49–51). The 
program ArchTex (52) was then used to map average histone 
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modifications surrounding the Ets1 consensus-binding sites. As 
a control, ArchTex was also used to align histone modifications 
surrounding 60,000 random consensus Ets1-binding sites from 
regions not bound by Ets1 in ChIP-seq assays.
To test if Ets1 might co-regulate some of the same genes as 
Pax5, Tcf3 (E2A), or Irf4, we obtained ChIP-seq data for these 
factors in primary mouse splenic B cells, as reported in Ref. (51, 
53, 54). We used Bedtools to identify the co-occurrence between 
peaks and common target sites for these transcription factors.
rna-seq analysis
Spleens from female WT (C57BL/6) and Ets1 knockout mice 
(C57 × 129Sv) were used to prepare single cell suspensions, and 
quiescent follicular B  cells were sorted from each population 
based on the following markers: B220+ CD23hi CD21low CD80neg 
IgAneg IgEneg IgG1neg IgG2aneg IgG2bneg IgG3neg using FACSAria 
II cell sorter. Dead cells were gated out from the sorted popula-
tion using Live/Dead Fixable Aqua dead cell stain (Molecular 
Probes). Total RNA was isolated from two biological replicates of 
sorted B cells and subjected to RNA-sequencing on an Illumina 
Hiseq2500 Sequencing System. Sequence reads (24–49  million 
per sample) were aligned to the mm9 genome assembly using 
the Tophat program, and differences in gene expression between 
samples were analyzed using Cuffdiff (55). For further analysis, 
we chose genes that showed a fold change between WT and 
Ets1−/− B cells of at least twofold [log2(FC) = 1.0 or more] and 
a q value of 0.05 or less. We excluded genes with a reported 
Fragments Per Kilobase of transcript per Million mapped reads 
(FPKM) of less than 1.0 in either genotype. CummeRbund was 
used to visualize the Cuffdiff analysis, including generating heat 
maps of gene expression levels.
Genes that showed an alteration in expression as described 
above were analyzed for their functions by DAVID software (56) 
to identify the most-relevant gene ontology (GO) terms that were 
significantly enriched. We used an EASE score equal to 0.05 and a 
count threshold of 5 to identify enriched pathways.
rna isolation and reverse  
Transcription-Pcr
To validate RNA-seq data, we purified B  cells from the 
spleens of 3-month-old male and female WT and Ets1−/− mice 
(C57BL/6 ×  129Sv genetic background) by first using magnet 
beads (Stem Cell Technologies mouse B  cell purification kit) 
followed by sorting mature naïve follicular B cell subset B220+ 
CD23hi CD21low CD11bneg CD80neg IgAneg IgEneg IgG1neg IgG2aneg 
IgG2bneg IgG3neg. RNA was extracted from sorted B cells (n = 4 
of each genotype) using Direct-zol RNA MiniPrep kits (Zymo 
Research). cDNA was synthesized from equal amounts of RNA 
using QuantiTect Reverse Transcription kit (Qiagen). Quantitative 
RT-PCR was performed using iQ SYBR Green Supermix (Bio-
Rad). The sequences of primers used for RT-PCR were: Slamf6  
(Forward-CAGCTAATGAATGGCGTTCTAGG, Reverse-CTT 
AGGTTGATAACGAGGGCAG), Egr1 (Forward-AACCGGCCC 
AGCAAGACACC, Reverse-TGGCAAACTTCCTCCCACAA 
AT), Ptpn22 (Forward-AGCAAGCCTACAGAACGTG, Reverse- 
TCCAGAGGTGCGTTACATATTC), Stat4 (Forward-TGGCAA 
CAATTCTGCTTCAAAAC, Reverse-GAGGTCCCTGGATAG 
GCATGT), Prdm1 (Forward-TGTGGTAATGTCGGGACTTTG, 
Reverse-TTCCTTTTGGAGGGATTGGAG), Hprt (Forward- 
CCTCATGGACTGATTATGGACAG, Reverse-TCAGCAAAGA 
ACTTATAGCCCC), Gapdh (Forward-AATGGTGAAGGTCG 
GTGTG, Reverse-GTGGAGTCATACTGGAACATGTAG), and 
Actb (β-actin) (Forward-GCAGCTCCTTCGTTGCCGGTC, 
Reverse-TTTGCACATGCCGGAGCCGTTG). Gene expression 
was normalized to all three housekeeping genes (Gapdh, Hprt, 
and Actb) using Bio-Rad CFX Manager Software.
retroviral Transduction
Plasmids encoding mouse Stat4 (57) or human myc-tagged 
Ptpn22 (58) were obtained from Dr. John O’Shea (National 
Institutes of Health, Bethesda, MD, USA) or Dr. Dimitar 
Efremov (International Centre for Genetic Engineering and 
Biotechnology, Rome, Italy), respectively. The cDNAs were cut 
from the original plasmids and sub-cloned into the MIGR1 
retroviral plasmid, which contains an internal ribosomal entry 
site (IRES) followed by GFP to allow easy identification of 
virally infected cells. The resulting plasmids were confirmed 
by sequencing. The MIGR1 plasmid encoding mouse Ets1 has 
been described previously (22). The plasmid used for Egr1 
knockdown was generated by cloning a shRNA against Egr1 into 
the microRNA-30-adapted shRNAmir retroviral vector (MSCV-
lmp) from Open Biosystems. Oligonucleotides with sense and 
antisense strands of an shRNA targeting nucleotides 2,314–2,336 
of mouse Egr1 mRNA (NM_007913.5) were cloned into MSCV-
lmp and confirmed by sequencing. MSCV-lmp also contains an 
IRES-GFP module that can be used for detecting transduction. A 
retroviral plasmid containing a shRNA against Prdm1 in MSCV-
lmp, where the GFP gene was substituted with a GFP variant 
Ametrine (59), was obtained from Dr. Matthew E. Pipkin (The 
Scripps Research Institute, Jupiter, FL, USA).
Retroviral plasmids were used to transfect the Plat-E packag-
ing cell line along with the plasmid pCL-Eco (which contains 
additional copies of the viral structural genes) using Fugene-6. 
The retroviral supernatant was harvested after 48 h of transfection 
and used to infect WT or Ets1−/− B cells that were purified using 
anti-B220 microbeads (Miltenyi Biotec) and stimulated with 
10 µg/ml of lipopolysaccharide (LPS) for 24 h. The infected B cells 
were subsequently returned to fresh medium containing LPS. 
Forty-eight hours later, B cells were stained for flow cytometry 
with antibodies to B220 and CD138. Just prior to flow cytometry, 
7AAD was added to allow exclusion of dead cells from analysis. 
Flow cytometry data were collected on a BD LSR II flow cytom-
eter and analyzed using FlowJo software.
To test viral gene expression, infected cells were harvested 
to make lysates. For the Stat4-virus infected cells, we detected 
expression in the packaging cell line Plat-E as well as in sorted 
GFP+ virally-infected B cells. For the other constructs, we 
used unsorted, infected B cells to make lysates. Protein expression 
was analyzed by Western blotting using the following mono-
clonal antibodies: anti-Ptpn22 (clone D6D1H; Cell Signaling 
Technology),  anti-Egr1 (clone T.126.1; Thermo Fisher Scientific), 
anti-Stat4 (clone C46B10; Cell Signaling Technology), anti-
Blimp1 (clone 6D3; EMD Millipore), and anti-GAPDH (clone 
6C5; EMD Millipore).
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statistical analysis
Statistical analysis for qPCR and ELISPOT assays were performed 
using GraphPad Prism software. p-Value was calculated using 
unpaired Student’s t-test with two-tailed p-value or with the 
Mann–Whitney U-test.
resUlTs
identification of ets1-Binding sites  
in the chromatin of B cells
To gain insight into how Ets1 mechanistically regulates B  cell 
differentiation, we assessed its genome-wide occupancy by 
chromatin immunoprecipitation followed by deep sequencing 
(ChIP-seq) using chromatin derived from mouse mature B cells. 
Purified splenic B  cells showed enhanced phosphorylation of 
Ets1 based on SDS-PAGE mobility when compared to whole 
spleen (Figure 1A). This shift in mobility arises from calcium-
induced CAM kinase-dependent serine phosphorylation (34, 
60) and results in inhibition of Ets1 DNA binding (61). In order 
to restore Ets1-binding activity, we rested the B cells for 1–2 h, 
which resulted in normalization of Ets1 phosphorylation status 
(Figure 1A). After the resting period, purified B cells were fixed 
and sonicated.
B cell chromatin was immunoprecipitated with an anti-Ets1 
antibody that has been used previously in chromatin immuno-
precipitation (40–42). We identified 10,391 reproducible peaks 
of Ets1 binding, which target 8,975 genes in B cells (GEO dataset: 
GSE83758). Among Ets1-bound regions, approximately half are 
in the promoters of the genes (within 3 kb of the transcriptional 
start site). An additional 20% are in the introns of genes and about 
27% are located in distal intergenic regions that may represent 
enhancers or silencers (Figure 1B). Less than 10% of Ets1-binding 
sites were detected in coding exons, the 5’ or 3’ UTRs of genes 
or within 3  kb downstream of target genes. We identified the 
consensus Ets1-binding motif in 68% of target sites (Figure 1C). 
Additional transcription factor motifs that were enriched in 
the Ets1-bound regions include combined ETS-RUNX sites, 
combined PU.1-IRF sites, IRF2 sites, STAT3 sites, and PAX5 sites 
(Figure 1C).
Pax5 is a key transcription factor that regulates B cell identity 
and limits differentiation to ASCs (62, 63). We have previously 
implicated Ets1 in controlling Pax5 levels in B  cells (22, 29). 
Indeed, examination of the ChIP-seq peaks of Ets1 showed 
several peaks in the Pax5 gene including one in the proximal 
promoter and several in introns of the gene including two strong 
peaks in intron 5 where a B cell-specific enhancer of Pax5 has 
been described (64) (Figure S1 in Supplementary Material). 
These observations support the idea that Ets1 may directly 
regulate expression of the Pax5 gene. Several strong Ets1-binding 
peaks were also detected near the Prdm1 gene, which encodes 
Blimp1 (Figure S2 in Supplementary Material). Although these 
regions are not associated with any known regulatory elements, 
they are enriched in H3K4me1 and H3K27Ac marks indicative 
that they may represent functional regulatory elements. When 
examining other genes that have been previously described as 
Ets1 targets [such as those encoding Cd79a (Igα), H-2Aa and 
H-2Eb1 (isoforms of MHC II), and Nfkb1 (p50)], we found that 
each gene contained nearby Ets1-binding sites (Figure S3 in 
Supplementary Material) and, therefore, is potentially regulated 
by Ets1 in vivo.
analysis of Patterns of ets1 Binding  
in B cells
To understand how Ets1 might regulate B cell responses, we ana-
lyzed pathways associated with Ets1 binding. Ets1-binding peaks 
were enriched in genes associated with immune response, antigen 
processing and presentation, immune signaling pathways, and 
mature B  cell differentiation (Figure  1D). Interestingly, Ets1-
binding peaks are located near a large number of genes involved 
in the BCR signaling cascade (Figure S4 in Supplementary 
Material). Additional non-immune pathways enriched in Ets1-
binding sites included genes involved in processing of non-coding 
RNA, protein folding, and apoptosis (data not shown).
The ENCODE project has mapped histone modifications and 
transcription factor-binding sites for various human and mouse 
cell lines (65, 66). In mature primary mouse B  cells, data are 
available for the H3K27me3 modification (49). In addition, two 
research groups have mapped histone modifications (H3K4me1, 
H3K4me2, H3K4me3, H3K9Ac, H3K27Ac, and H3K27me3) in 
primary mouse B cells (50, 51). We tested whether any of these 
histone marks showed enrichment near the Ets1-binding peaks 
as compared to random chromatin. We found that peaks of 
H3K4me3 (associated with promoters) were strongly enriched on 
either side of the peak Ets1-binding locus (Figure 1E). Similarly, 
peaks of H3K4me2, H3K9Ac, and H3K27Ac (associated with 
both promoters and enhancers) were also strongly enriched 
flanking the Ets1-binding sites. Weaker enrichment of H3K4me1 
(associated with enhancers) was also observed flanking Ets1-
binding sites, while there was no enrichment of H3K27me3 
(associated with repressed genes) near Ets1-binding peaks. None 
of the histone marks showed specific enrichment when random 
chromatin regions were used (not shown). These data indicate 
that binding of Ets1 is strongly associated with active promoters 
and enhancers of genes, but is associated weakly if at all with 
repressed sites.
ChIP-seq datasets are also available for Pax5 in mouse mature 
splenic B cells (51). We compared the binding sites of Pax5 with 
those bound by Ets1 to identify genes that might be co-regulated. 
There were 4,590 overlapping peaks common between Ets1 and 
Pax5 (Figure 2A), representing ~44% of all Ets1-bound regions 
and ~45% of all Pax5-bound regions. Among the genes having 
peaks for both Ets1 and Pax5 are some that encode genes that are 
crucial for B cell biology including CD79a, ICOS ligand, Foxp1, 
PLCγ2, and Vav1. Ontology enrichment analysis of the identified 
common targets of Ets1 and Pax5 indicate that they are associ-
ated with immune system activation and effector processes (not 
shown). This suggests that there is a strong overlap in function of 
Ets1 and Pax5 in B cells.
Binding sites for Tcf3 (E2A) (53) and Irf4 (54) have also been 
mapped in primary B cells. We found that ~47% of E2A-binding 
sites overlap with those of Ets1 (Figure 2B). These overlapping 
binding sites include genes such as Cd19, Blnk, and Rasgrp1. With 
Irf4, relatively few (865) binding sites were detected in primary 
FigUre 1 | identification of ets1-binding sites in mouse B cells. (a) Western blot to show phosphorylation of Ets1 in freshly isolated B cells versus rested 
B cells. GAPDH serves as loading control. (B) Pie chart of location of Ets1 sites in the genome. (c) Motifs enriched in Ets1-bound regions. Shown are 
overrepresented transcription factor-binding motifs localized in the Ets1 peaks and the percent of sites with that motif. (D) Gene ontology biological terms 
associated with Ets1-binding peaks in B cells. (e) Analysis of epigenetic features surrounding Ets1-bound regions by mapping adjacent histone modifications.  
Data come from the ENCODE Consortium or from the studies described in Ref. (50, 51).
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FigUre 2 | ets1-binding sites overlap with those of other B cell transcription factors. Venn diagrams to show overlap between Ets1-bound regions in 
primary mouse B cells with (a) Pax5-bound regions, (B) E2A-bound regions, and (c) Irf4-bound regions. Pax5, E2A, and Irf4 ChIP-seq data come from studies 
described in Ref. (51, 53, 54).
6
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naïve B  cells (Figure  2C). However, of these 865 sites, ~58% 
overlap with Ets1-binding sites, including sites in important 
B cell genes such as Cxcr4, Cxcr5, Lyn, Pax5, Ebf1, and Foxo1. 
Overall, these studies show that Ets1 is targeted to promoters 
and/or enhancers of genes important for B  cell activation and 
differentiation and can potentially co-regulate such genes along 
with other B cell transcription factors like Pax5, E2A, and Irf4.
identification of changes in gene 
expression in the absence of ets1
The presence of a binding site for a transcription factor does not 
always correlate with its ability to activate or repress transcription 
from the gene. To better identify genes in B cells whose expres-
sion directly depends on Ets1, we performed RNA-sequencing 
using RNA isolated from WT and Ets1–/− splenic B cells (GEO 
Dataset: GSE83797). One potential complicating factor is that 
Ets1−/− mice have different B  cell composition in the spleen, 
because they lack marginal zone B  cells and their follicular 
B cells (1) have a more activated phenotype, (2) undergo altered 
isotype-switching, and (3) differentiate at higher rates to ASCs 
than their WT counterparts (23, 25, 26, 36, 67). Therefore, to 
compare similar populations of B  cells from WT and Ets1−/− 
mice, we used flow cytometry to isolate follicular B cells (B220+ 
CD23hi CD21low) that were not activated (CD80neg) and had not 
undergone class-switching (IgAneg IgEneg IgG1neg IgG2aneg IgG2bneg 
IgG3neg) (Figure 3A). We avoided sorting B cells based on surface 
levels of IgM or IgD, because we did not want to activate the cells 
by cross-linking the antigen receptor. Total RNA was prepared 
from sorted B cell subsets from each genotype and subjected to 
deep sequencing.
We identified a list of genes that showed at least a twofold change 
in expression between WT and Ets1−/− B cells with a q-value of 
0.05 or less and with a FPKM value of at least 1.0 in either geno-
type. Using these criteria, 484 genes showed altered expression in 
the absence of Ets1 (Figure 3B). Of these, the expression of 208 
genes (43%) was downregulated in the absence of Ets1, suggesting 
that Ets1 activates the expression of those genes. The expression 
of 276 genes (57%) was upregulated in the absence of Ets1, sug-
gesting that Ets1 might repress these genes (Figure 3B). Overall, 
the changes in expression of potential Ets1 target genes were 
mostly moderate (typically in the range of twofold to fourfold 
differences between WT and Ets1−/−). Unexpectedly, we found 
that the Pax5 gene was not one of those genes whose expression 
was altered in the absence of Ets1 (Figure S5 in Supplementary 
Material). Functional annotation of the molecular pathways 
that are overexpressed in Ets1−/− B cells (i.e., pathways repressed 
by Ets1) showed that they were predominantly associated with 
inflammatory responses and chemotaxis (Figure 3C; Figure S6A 
in Supplementary Material). In contrast, the molecular pathways 
that are under-expressed in Ets1−/− B cells (pathways activated by 
Ets1) were associated with immune cell signal transduction and 
activation (Figure 3D; Figure S6B in Supplementary Material). 
Thus, Ets1 is an important regulator of B  cell functions by 
both positively and negatively regulating various aspects of the 
immune response.
genes implicated in autoimmunity are 
among Those controlled by ets1
We compared the ChIP-seq dataset that contained binding 
sites for Ets1 to the RNA-seq dataset that showed which genes 
FigUre 3 | identification of genes whose expression in B cells requires ets1. (a) Scheme to isolate naive follicular B cells from the spleens of wild-type (WT) 
and Ets1−/− mice (n = 2 samples/genotype). (B) Scatterplot analysis of differential gene expression in WT and Ets1−/− B cells. Genes that are upregulated (Ets1-
repressed) in Ets1−/− cells are shown as green dots, while genes that are downregulated (Ets1-activated) are shown as red dots. Gray dots are genes whose 
expression does not change and/or whose expression is less than 1.0 FKPM in both cell types. Dots with yellow centers are the genes that show an associated 
Ets1-binding site by ChIP-seq. Pathway analysis of genes repressed (c) and activated (D) by Ets1. The top 10 GO terms ranked according to p-value are shown for 
both Ets1-repressed and Ets1-activated genes.
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changed expression in Ets1−/− B cells to find genes that might be 
directly regulated by Ets1. There were 263 genes that contained 
a nearby Ets1-binding peak and showed an alteration in expres-
sion in the absence of Ets1 (Figure 4A). This represents ~3% of 
genes containing Ets1-binding peaks. Among these genes, 137 
(~52%) are activated by Ets1 and 126 (~48%) are repressed by 
Ets1. Examining the list of 263 genes, we identified numerous 
putative Ets1 target genes where SNPs have been associated with 
autoimmune disease susceptibility (Table  1). Additional Ets1 
target genes include ones important for immune function such 
as Il5ra, Tlr1, Traf4, and Ltk, but that not yet been implicated as 
susceptibility loci for autoimmune disease. In further studies, we 
focused on those genes listed in Table 1, because of their known 
associations with immune regulation and autoimmune disease 
susceptibility.
We selected a subset of potential Ets1 target genes and 
designed primers to test their expression in qRT-PCR. The genes 
selected for further analysis were Egr1, Stat4, Prdm1, Slamf6, and 
Ptpn22 as shown in Figure 4B and Figure S7 in Supplementary 
Material. qRT-PCR analysis showed that Egr1, Stat4, Prdm1, and 
Ptpn22 all displayed a pattern of expression consistent with the 
RNA-seq results (Figure 4C). On the other hand, expression of 
Slamf6 did not appear to change in the absence of Ets1 in this 
analysis.
FigUre 4 | genes that are potential direct targets of ets1. (a) Venn diagram of overlap of ChIP-seq dataset with genes upregulated in the absence of Ets1 
(276 genes) or downregulated in the absence of Ets1 (208 genes). (B) Heat map of selected Ets1 target genes associated with autoimmunity. (c) qPCR analysis of 
the expression of the target genes shown in part B (n = 4 for each genotype) using cDNA from sorted (B220+ CD23hi CD21low CD11bneg CD80neg IgAneg IgEneg IgGneg) 
follicular B cells. Shown is average ±SEM, *p < 0.05.
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Stat4 and Ptpn22 showed decreased expression in the absence 
of Ets1, while Egr1 and Prdm1 are elevated. Therefore, Ets1 may 
promote the expression of Stat4 or Ptpn22, while suppressing 
expression of Egr1 or Prdm1. Alternatively, these changes in 
Stat4, Ptpn22, Egr1, and Prdm1 may instead represent secondary 
changes in gene expression that reflect the fact that Ets1–/− B cells 
are primed to become activated and differentiate to ASCs, rather 
than being important drivers of the Ets1–/− B cell phenotype. If 
Ptpn22 or Stat4 were target genes that mediated the effects of Ets1 
on B cell differentiation, then we would expect that expression 
of Stat4 and Ptpn22 in B cells might in part mimic the effects of 
expression of Ets1, such as its ability to suppress ASC generation. 
To test this, we cloned cDNAs encoding Stat4 and Ptpn22 into a 
retroviral vector so that we could restore expression of these genes 
to Ets1−/− B  cells and overexpress them in WT B  cells. WT or 
Ets1−/− splenic B cells were stimulated with LPS and infected with 
control virus (MIGR1), virus-expressing Ets1 (MIGR1-Ets1), or 
viruses-expressing Stat4 or Ptpn22 (MIGR1-Stat4 or MIGR1-
Ptpn22). We monitored cellular differentiation to ASCs (B220low 
CD138+) using flow cytometry in the GFP+ virally infected cells.
Western blot using extracts of virally infected B cells showed 
that B  cells infected with Ptpn22 virus overexpress Ptpn22 
(Figure 5A). Retrovirally expressed Stat4 was also easily detect-
able in the packaging cell line (Figure 5A), but its overexpression 
in B cells was less obvious due to the high levels of endogenous 
Stat4 in this cell type (Figure  5A). Viruses encoding Stat4 
or Ptpn22 reproducibly resulted in low percentages of GFP+ 
virally infected B cells (5–10%) and low intensity of GFP stain-
ing, while empty virus or virus encoding Ets1 resulted in high 
percentages (40–80%) of GFP+ cells and high intensity of GFP 
staining (Figure 5B). Expression of Ets1 suppresses development 
of B220loCD138+ plasmablasts compared to B cells infected with 
empty vector (MIGR1) (Figure  5C). On the other hand, we 
found that there was a dramatic increase in the B220loCD138+ 
plasmablast cell numbers in B cells expressing Stat4 or Ptpn22 
(Figure 5D), indicating that these genes stimulate the develop-
ment of ASCs.
Unlike Stat4 and Ptpn22, Egr1 and Prdm1 were upregulated in 
Ets1−/− B cells by about twofold to threefold, suggesting that Ets1 
represses expression of these genes. We used a retroviral vector 
encoding shRNAs to knockdown expression of these genes in 
B cells (Figure 6A) (59). Expression of shRNA against Egr1 was 
effective in reducing levels of Egr1 protein in stimulated B cells 
(Figure  6B), but did not impair formation of B220lowCD138+ 
plasmablasts (Figures 6C–E). The Prdm1 shRNA was also able 
to knockdown expression, although it was less efficient in Ets1−/− 
B cells (Figure 6B and data not shown). The Prdm1 shRNA did not 
alter ASC differentiation in WT or Ets1−/− B cells (Figures 6C–E), 
despite the fact that Blimp1 is known to be essential for plasma 
cell generation. This is likely because sufficient Blimp1 is still 
expressed to allow ASC differentiation. To further assess the role 
of Prdm1 in the phenotype of Ets1−/− B cells, we crossed Ets1−/− 
mice to mice carrying a GFP knock in allele in the Prdm1 locus 
that disrupts expression of the Prdm1 gene and leads to reduced 
levels of full-length functional Blimp1 protein (104). Homozygous 
Prdm1 knockout mice carrying this allele die embryonically due 
to a combination of developmental defects, but heterozygous 
mice are viable (104). We generated Ets1−/−Prdm1gfp/+ mice that 
TaBle 1 | list of potential ets1 target genes associated with autoimmune disease.
gene name change in 
Ets1−/− B cells
autoimmune diseases linked to single-nucleotide 
polymorphisms in the gene (reference)
Function
Antxr2 Downregulated (4X) Ankylosing spondylitis (68) Membrane protein-binding extracellular matrix; unknown function in 
B cells
Ccdc88b Downregulated (2X) Sarcoidosis (69) Coiled-coil domain protein of unknown function in B cells
Cr2 Downregulated (2.3X) Systemic lupus erythematosus (70) Receptor on B cells that binds complement fragment C3d
Gimap4 Downregulated (2.2X) Behcet’s disease (71) GTPase of unknown function in B cells
Ifi30 Upregulated (2.2X) Multiple sclerosis (72) Enzyme involved in antigen processing in B cells
Il6ra Downregulated (2.3X) Rheumatoid arthritis, type I diabetes (73) Receptor for cytokine IL-6 involved in stimulating B cell proliferation 
and antibody-secreting cells (ASCs) formation
Itgam Upregulated (3.3X) Systemic lupus erythematosus (74); systemic  
sclerosis (75)
Integrin subunit involved in regulating BCR signaling
Nod2 Upregulated (5.2X) Psoriasitic arthritis (76); Behcet’s disease (77) Receptor for bacterial products like muramyl dipeptide; triggers 
NFκB activation in B cells
Pdcd1lg2 Downregulated (2.2X) Ankylosing spondylitis (78) Membrane-bound ligand for the PD-1 receptor that inhibits T cell 
activation
Pde2a Downregulated (4X) Rheumatoid arthritis (79) Enzyme that degrades cAMP; unknown function in B cells
Prdm1 Upregulated (2.5X) Systemic lupus erythematosus (80); rheumatoid  
arthritis (81)
Transcription factor driving ASC formation
Ptpn22 Downregulated (2.1X) Type I diabetes (82); rheumatoid arthritis (83); systemic 
lupus erythematosus (84); antineutrophil cytoplasmic 
antibody-associated vasculitis (85); psoriatic arthritis (86); 
Myasthenia gravis (87); Graves’ disease (88)
A phosphatase that can regulate BCR signaling; variably reported to 
either enhance or suppress B cell responses
slamf6 Upregulated (2.8X) Graves’ disease (89) Membrane receptor implicated in controlling B cell tolerance to 
self-antigens
stat4 Downregulated (2.9X) Behcet’s disease (90); rheumatoid arthritis (91); systemic 
lupus erythematosus (92); psoriasis (93); Sjogren’s 
syndrome (94); systemic sclerosis (95)
Transcription factor-mediating IL-12 signaling in B cells
Tlr1 Downregulated (4.6X) Type I diabetes (96); Graves’ disease (97); alopecia 
areata (98)
Receptor with TLR2 to form a receptor for bacterial triacyl 
lipopeptide
Traf1 Downregulated (4.9X) Rheumatoid arthritis (91); systemic lupus erythematosus 
(99); alopecia areata (100)
Signal transduction molecule that can associate with various TNF 
receptor family members including CD40, OX40, BCMA, and TACI
Zc3h12c Upregulated (2.1X) Psoriasis (101) Transcription factor that inhibits inflammatory cytokine production
Zmiz1 Downregulated (2.7X) Vitiligo (102); psoriasis (103) PIAS-like co-regulator protein that is involved in regulating activity of 
transcription factors like p53 and Smads
Genes noted in bold text are those which we follow-up on further in this report.
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of autoantibodies. In this study, we show that Ets1 binds to and is 
required for normal expression of ~260 genes in mature B cells, 
including a subset of genes highly linked to immune responses 
and autoimmune disease susceptibility.
A large percentage (~50%) of the Ets1-binding sites, we identi-
fied in primary B  cells, are localized in proximal promoters of 
genes in regions enriched for histone marks associated with active 
promoters (H3K4me3, H3K4me2, H3K9Ac, and H3K27Ac). 
Such a high percentage of binding sites in the proximal promoter 
is not always the case in ChIP-seq analyses of transcription fac-
tors. For instance, a ChIP-seq study of PU.1 and SpiB binding 
in the WEHI-279 B cell line found only ~15% of binding sites 
localized in the proximal promoter (105). Similarly, analysis of 
Runx1 binding in pro-B cells found that only ~10% of sites were 
in the proximal promoter of target gene (106). On the other hand, 
ChIP-seq analysis of Ets1 binding in human hematopoietic and 
embryonic stem cell lines showed that Ets1 binding was enriched 
in the promoter regions of genes in these cell types (107), although 
in the same study Ets1 binding was fairly equally distributed 
between promoters and enhancers in mouse cell lines. In the 
human Jurkat T cell line, Ets1 was shown to bind redundantly 
to proximal promoters of housekeeping genes along with other 
carry a single copy of Prdm1 and express reduced levels of Blimp1 
(Figure  7A). The numbers of ASCs in these mice and control 
mice was quantitated using ELISPOT, which showed that reduced 
levels of Prdm1 was not sufficient by itself to restrain excess ASC 
formation in the absence of Ets1 (Figure 7B). In summary, the 
changes in expression of the genes we tested (Stat4, Ptpn22, Egr1 
and Prdm1) cannot by themselves explain the effects of Ets1 on 
ASC formation.
DiscUssiOn
Over time, evidence has accumulated that Ets1 is a key regulator of 
B cell differentiation and that reduced levels of Ets1 are associated 
with the development of autoimmune diseases. We previously 
demonstrated that Ets1 controls B cell differentiation in part via 
the ability of Ets1 protein to directly bind to the Blimp1 protein 
and prevent Blimp1 interaction with DNA (22, 29). However, it 
remains unclear whether this protein–protein interaction is the 
main mechanism by which Ets1 inhibits B cell differentiation into 
ASCs or not. Because Ets1 is a transcription factor, it is important 
to understand what genes Ets1 regulates in B cells and how they 
may contribute to the control of B cell differentiation and secretion 
FigUre 5 | continued
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FigUre 5 | continued  
restoration of selected target genes in Ets1−/− B cells. (a) Western blot analysis of Ptpn22 [with lysates from unsorted virally infected wild-type (W) and 
knockout (K) B cells] and Stat4 expression [with lysates from the packaging cell line (PLAT-E) or virally infected B cells (B cells); note that the small text under the 
Stat4 blot represents Stat4 expression levels normalized to GAPDH]. (B) Green fluorescent protein (GFP) profiles of virally infected cells. Red shaded curves are 
background staining of control non-infected cells, while open black curves are GFP staining in virally infected cells. Bold red type is the mean fluorescent intensity of 
GFP in the GFP+ gated population. (c) Analysis of GFP+ WT and Ets1−/− B cells to show differentiation to B220-low CD138+ plasmablasts (boxed). (D) Mean ± SEM 
of the percentage of plasmablasts within the GFP+ population in three independent viral infection experiments.
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members of the Ets gene family, but to bind specifically to distal 
T cell enhancers (108). We found a similar pattern in primary 
mouse B cells, where Ets1 tends to bind only to the promoter of 
genes that have housekeeping functions (not shown). However, 
when Ets1 binds to distal regulatory elements (e.g., enhancer 
sequences) or to both promoters and distal regulatory sequences, 
those genes tend to be involved in specific B cell immune response 
pathways.
We previously showed that Ets1 can bind to the Pax5 gene, 
transactivate the Pax5 promoter and sustain Pax5 expression in 
differentiating B cells (22, 29). Here we confirm using ChIP-seq 
that Ets1 binds to both the Pax5 promoter and to the intron 5 
B  cell-specific enhancer of Pax5. However, somewhat surpris-
ingly the levels of Pax5 mRNA are not significantly changed 
in Ets1−/− B  cells as compared to WT B  cells, as detected by 
RNA-sequencing. Several explanations could account for this. 
First, other Ets family members expressed in B cells (such as Fli1, 
Spi1, Spib, Elk4, Elf1, Elf2, Gabpa, and/or Etv3) could bind to 
these sites in the absence of Ets1 and compensate to maintain 
Pax5 expression. Supporting a potentially redundant role for Ets 
family transcription factors in regulating Pax5 gene expression, 
the Ets protein PU.1 can also bind to Pax5 enhancer sequences 
(64, 109). Alternatively, Ets1, specifically, may be required to 
maintain Pax5 expression, but may only regulate the gene at 
certain stages of development or in response to certain stimuli. 
Finally, it is also possible that the Ets-binding sites at these 
regions might represent fortuitous binding without functional 
significance. Similar arguments may be made for the many other 
genes in which we detected Ets1 binding, but whose expression 
does not change in B cells lacking Ets1. For instance, we found 
that Ets1-binding sites were detected in many genes involved in 
the BCR signaling pathway. Yet, the expression of most of these 
genes was unchanged in the absence of Ets1. Indeed, only ~3% of 
genes with a nearby Ets1-binding site showed altered expression 
in mature Ets1 knockout B cells.
Interestingly, among the genes identified that had at least one 
Ets1-binding site nearby and whose expression changed in Ets1−/− 
B cells, we found many that have previously been implicated in 
immune responses and autoimmune disease susceptibility based 
on genome-wide SNP assays. We chose two genes whose expres-
sion is reduced in Ets1−/− B cells (Stat4 and Ptpn22) and restored 
their expression using retroviral vectors. An unexpected result 
of our study is that expression of either Stat4 or Ptpn22 has an 
opposite effect to the expression of Ets1 (i.e., Ets1 expression 
suppresses LPS-induced plasmablast formation, while Stat4 and 
Ptpn22 both promote this process). This observation is interest-
ing in light of the fact that Stat4 and Ptpn22 are both strongly 
associated with susceptibility to multiple different autoimmune 
diseases (110, 111).
Stat4 is best known as a transcription factor activated 
downstream of IL-12 signaling where it plays an important role in 
the production of IFN-γ (112). In B cells, Stat4 and IL-12 signal-
ing have been most closely linked to differentiation of B cells to 
B effector type 1 (Be1) cells that secrete IFN-γ (113). However, 
our results suggest that Stat4 has additional B cell-intrinsic effects 
that promote the formation of ASCs, since retrovirally induced 
production of Stat4 potentiated LPS-induced formation of 
B220loCD138+ plasmablasts. This was true even though Stat4 was 
expressed at low levels in B cells using our retroviral construct. 
This effect of Stat4 may be independent of its roles in promoting 
IFN-γ production, although further studies are needed to con-
firm this. Recent data show that a lupus-associated SNP in the 
STAT4 gene leads to increased Stat4 expression (114), supporting 
the idea that higher Stat4 expression may promote autoimmunity. 
Interestingly, knockout of the Stat4 gene reduces autoantibody 
production in lupus-prone B6.TC mice (115). These results 
are consistent with the data in this manuscript that show Stat4 
expression is increased in B cells from autoimmune-prone Ets1−/− 
mice and that Stat4 expression in B cells potentiates development 
of ASCs.
We found that retroviral expression of Ptpn22 also potentiates 
formation of plasmablasts in response to LPS. In myeloid cells, 
Ptpn22 promotes TLR signaling by stimulating Traf3 autoubiq-
uitination (116). It may play a similar role in B  cells, resulting 
in increased LPS-derived signals that promote ASC generation. 
Altogether, our data indicate that Stat4 and Ptpn22 have oppo-
site roles compared to Ets1 in regulating formation of ASCs in 
response to LPS stimulation. The low levels of Stat4 and Ptpn22 
transcripts in Ets1−/− B cells may, therefore, be due to secondary 
changes in the cells in an attempt to compensate for excessive 
B cell activation and differentiation in the absence of Ets1.
We also investigated roles for two genes whose expression 
is upregulated in Ets1−/− B  cells, Egr1, and Prdm1. Recently, 
B  cells lacking Egr1 were shown to undergo reduced differen-
tiation to CD138+ plasmablasts when cultured with LPS (117). 
Furthermore, Egr1 knockout mice secrete less antigen-specific 
antibody in response to immunization with a T-dependent anti-
gen (117). Since Egr1 is overexpressed in Ets1−/− B cells, reducing 
the levels of this gene might be expected to reverse the phenotype 
of Ets1−/− B cells and reduce ASC numbers. We used shRNA to 
knockdown Egr1 in B cells undergoing differentiation and found 
that this did not change ASC generation in either WT or Ets1−/− 
B cells. Thus, Egr1 appears not to be an essential Ets1 target gene 
regulating B cell differentiation, but rather is likely upregulated as 
a secondary consequence of B cell activation.
Ets1-binding sites are found in the Prdm1 locus and Ets1 
has previously been suggested to directly repress transcription 
of the Prdm1 gene in Th1-skewed T  cells (118). Since Blimp1, 
FigUre 6 | continued
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FigUre 7 | reduction of selected target genes in Ets1−/− B cells. (a) Analysis of Blimp1 expression in lipopolysaccharide-stimulated Ets1+/+, Ets1−/−, and 
Ets1−/−Prdm1+/gfp B cells. The location of the full-length wild-type and the truncated proteins is indicated on the panel. (B) ELISPOT analysis of the numbers of IgM- 
and IgG-secreting cells in the spleens of unchallenged mice of the indicated genotypes (n = 4–5 for each genotype). *p < 0.05, **p < 0.01, and ***p < 0.001.
FigUre 6 | continued  
reduction of selected target genes in Ets1−/− B cells. (a) Diagram of the retroviral construct encoding shRNAs used for knock down of gene expression in 
B cells. (B) Egr1 and Blimp1 expression analyzed by Western blot in lysates of B cells infected with shRNA viruses. (c) Green fluorescent protein (GFP) (MSCV and 
Egr1) and Ametrine (Prdm1) profiles of virally infected cells. Bold red type is the mean fluorescent intensity of GFP (or Ametrine) in the GFP+ (or Ametrine+) gated 
population. (D) B220 versus CD138 staining in the GFP+ (or Ametrine+) cells to show differentiation to B220-low CD138+ plasmablasts (boxed). (e) Mean ± SEM of 
the percentage of plasmablasts within the GFP+ (or Ametrine+) population in three independent viral infection experiments.
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the protein encoded by the Prdm1 gene, is a key transcription 
factor driving ASC formation, it is reasonable to assume that the 
approximately twofold upregulation of Prdm1 in Ets1−/− B cells 
might explain their propensity to differentiate to ASCs. To test 
this, we used both knockdown of Prdm1 in cultured B cells as well 
as gene-targeted mice. Knockdown of Prdm1 by shRNA did not 
impair ASC generation, potentially, because the knockdown did 
not fully eliminate Blimp1 expression. As an alternative approach 
to test whether reducing Blimp1 levels could restore normal ASC 
differentiation to mice lacking Ets1, we crossed Ets1−/− mice 
with mice carrying a heterozygous GFP knock in mutation in 
the Blimp1 locus that reduces Blimp1 expression by 50%. In the 
resulting Ets1−/−Prdm1gfp/+ mice, Blimp1 levels in Ets1−/− B cells 
are normalized. Yet, these mice still show an excess of splenic 
ASCs. Therefore, Ets1-dependent repression of Blimp1 expres-
sion does not seem to be an essential mechanism for preventing 
ASC generation.
cOnclUsiOn
Our study has provided a genome-wide list of target genes for the 
key B cell transcription factor Ets1. Given that normal expression 
of Ets1 is required to prevent autoimmune disease, it is interest-
ing that a number of these Ets1 target genes are genes identified 
as susceptibility alleles of autoimmune diseases. We expect that 
our results will be helpful in gaining insight into the molecular 
mechanisms that contribute to autoimmune disease and the roles 
of B cells in this process.
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FigUre s1 | ets1-binding sites in the Pax5 gene. The genomic locus of the 
mouse Pax5 gene (bottom) with Ets1-binding sites indicated as black bars along 
the top of the figure and by vertical columns of yellow shading. Note that Ets1 is 
strongly enriched at the promoter and in Intron 5 where a known B cell-specific 
enhancer is localized. Also shown are peaks of H3K27 acetylation and H3K4 
monomethylation derived from the mouse ENCODE datasets, which mark active 
enhancers and promoters.
FigUre s2 | ets1-binding sites in the Prdm1 gene. The genomic locus 
of the mouse Prdm1 gene (bottom) with Ets1-binding sites indicated as 
black bars along the top of the figure and yellow shaded vertical columns. 
Note that Ets1 is enriched in Intron 3 as well as sequences localized 50 kb 
downstream of the gene and sequences localized ~180 kb upstream of 
Prdm1.
FigUre s3 | ets1 binding sites in previously described target genes. The 
genomic loci encoding Nfkb1 (p50), Cd79a (Igα), and H-2Aa and H-2Eb1 (MHC 
II isoforms), genes that have previously been described as Ets1 targets based 
on transient transfection assays. Each gene is shown in a format similar to that 
described for Figures S1 and S2 in Supplementary Material. Note that each 
gene contains Ets1-binding sites in the promoter and other nearby regions 
based on ChIP-seq, supporting the idea that these are true functional target 
genes of Ets1.
FigUre s4 | ets1-binding sites are found in a large percentage of genes 
involved in Bcr signaling. BCR signaling cascade analyzed by IPA software. 
Genes encoding proteins outlined in purple contain one or more Ets1-binding 
sites nearby.
FigUre s5 | expression of Pax5 is not altered in ets1-deficient B cells. 
RNA-seq profiles for the Ets1 gene, the Pax5 gene, and a constitutively 
expressed housekeeping gene Ppia (peptidylprolyl isomerase A). Neither Pax5 
nor Ppia shows any change in transcription in Ets1−/− B cells. Overall, Ets1 
transcription is also not reduced in Ets1−/− B cells, but the exons that are 
targeted in the knockout (part of the second exon and the third exon) show 
reduced/absent transcription.
FigUre s6 | heat maps to show expression changes of genes in certain 
selected pathways identified by gene ontology analysis. Heat maps of the 
genes identified in the (a) defense response and (B) protein phosphorylation 
pathways showing clustering of wild-type and knockout B cells. Genes 
associated with autoimmune disease susceptibility that are further studied in this 
manuscript are highlighted by red type.
FigUre s7 | ets1-binding sites in the Egr1, Stat4, Slamf6, and Ptpn22 
genes. The genomic loci of the mouse Egr1, Stat4, Slamf6, and Ptpn22 genes 
with Ets1-binding regions shown along the top as black bars and as yellow 
shaded vertical columns. Also shown are peaks of H3K27 acetylation and H3K4 
monomethylation derived from the mouse ENCODE datasets, which mark active 
enhancers and promoters.
reFerences
1. Nutt SL, Urbanek P, Rolink A, Busslinger M. Essential functions of Pax5 
(BSAP) in pro-B  cell development: difference between fetal and adult B 
lymphopoiesis and reduced V-to-DJ recombination at the IgH locus. Genes 
Dev (1997) 11(4):476–91. doi:10.1101/gad.11.4.476 
2. Zandi S, Mansson R, Tsapogas P, Zetterblad J, Bryder D, Sigvardsson M. 
EBF1 is essential for B-lineage priming and establishment of a transcrip-
tion factor network in common lymphoid progenitors. J Immunol (2008) 
181(5):3364–72. doi:10.4049/jimmunol.181.5.3364 
3. Zhuang Y, Soriano P, Weintraub H. The helix-loop-helix gene 
E2A is required for B  cell formation. Cell (1994) 79(5):875–84. 
doi:10.1016/0092-8674(94)90076-0 
4. Mikkola I, Heavey B, Horcher M, Busslinger M. Reversion of B cell com-
mitment upon loss of Pax5 expression. Science (2002) 297(5578):110–3. 
doi:10.1126/science.1067518 
5. Cobaleda C, Jochum W, Busslinger M. Conversion of mature B  cells into 
T  cells by dedifferentiation to uncommitted progenitors. Nature (2007) 
449(7161):473–7. doi:10.1038/nature06159 
6. Nechanitzky R, Akbas D, Scherer S, Gyory I, Hoyler T, Ramamoorthy S, et al. 
Transcription factor EBF1 is essential for the maintenance of B cell identity 
and prevention of alternative fates in committed cells. Nat Immunol (2013) 
14(8):867–75. doi:10.1038/ni.2641 
7. Dengler HS, Baracho GV, Omori SA, Bruckner S, Arden KC, Castrillon DH, 
et al. Distinct functions for the transcription factor Foxo1 at various stages 
of B cell differentiation. Nat Immunol (2008) 9(12):1388–98. doi:10.1038/
ni.1667 
8. Turner  CA Jr, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing 
protein that can drive the maturation of B lymphocytes into immunoglobulin- 
secreting cells. Cell (1994) 77(2):297–306. doi:10.1016/0092-8674 
(94)90321-2 
9. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, et al. Blimp-1 
orchestrates plasma cell differentiation by extinguishing the mature B  cell 
gene expression program. Immunity (2002) 17(1):51–62. doi:10.1016/
S1074-7613(02)00335-7 
10. Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi-Tsuda E, 
Gravallese EM, et  al. Plasma cell differentiation requires the transcription 
factor XBP-1. Nature (2001) 412(6844):300–7. doi:10.1038/35085509 
11. Taubenheim N, Tarlinton DM, Crawford S, Corcoran LM, Hodgkin PD, 
Nutt SL. High rate of antibody secretion is not integral to plasma cell differ-
entiation as revealed by XBP-1 deficiency. J Immunol (2001) 189(7):3328–38. 
doi:10.4049/jimmunol.1201042 
12. Klein U, Casola S, Cattoretti G, Shen Q, Lia M, Mo T, et al. Transcription fac-
tor IRF4 controls plasma cell differentiation and class-switch recombination. 
Nat Immunol (2006) 7(7):773–82. doi:10.1038/ni1357 
13. De Silva NS, Simonetti G, Heise N, Klein U. The diverse roles of IRF4 in 
late germinal center B-cell differentiation. Immunol Rev (2012) 247(1):73–92. 
doi:10.1111/j.1600-065X.2012.01113.x 
14. Garrett-Sinha LA. Review of Ets1 structure, function, and roles in immunity. 
Cell Mol Life Sci (2013) 70:3375–90. doi:10.1007/s00018-012-1243-7 
15
Saelee et al. Ets1 Regulates Autoimmune-Associated Genes
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 383
15. Zhang XK, Moussa O, LaRue A, Bradshaw S, Molano I, Spyropoulos DD, 
et al. The transcription factor Fli-1 modulates marginal zone and follicular 
B cell development in mice. J Immunol (2008) 181(3):1644–54. doi:10.4049/
jimmunol.181.3.1644 
16. Bradshaw S, Zheng WJ, Tsoi LC, Gilkeson G, Zhang XK. A role for Fli-1 in 
B cell proliferation: implications for SLE pathogenesis. Clin Immunol (2008) 
129(1):19–30. doi:10.1016/j.clim.2008.05.010 
17. Xue HH, Bollenbacher-Reilley J, Wu Z, Spolski R, Jing X, Zhang YC, 
et  al. The transcription factor GABP is a critical regulator of B lym-
phocyte development. Immunity (2007) 26(4):421–31. doi:10.1016/j.
immuni.2007.03.010 
18. Carotta S, Wu L, Nutt SL. Surprising new roles for PU.1 in the adaptive immune 
response. Immunol Rev (2010) 238(1):63–75. doi:10.1111/j.1600-065X. 
2010.00955.x 
19. DeKoter RP, Geadah M, Khoosal S, Xu LS, Thillainadesan G, Torchia J, et al. 
Regulation of follicular B cell differentiation by the related E26 transforma-
tion-specific transcription factors PU.1, Spi-B, and Spi-C. J Immunol (2010) 
185(12):7374–84. doi:10.4049/jimmunol.1001413 
20. Lee CM, Gupta S, Parodo J, Wu J, Marshall JC, Hu J. The uncovering 
of ESE-1 in human neutrophils: implication of its role in neutrophil 
function and survival. Genes Immun (2015) 16(5):356–61. doi:10.1038/
gene.2015.10 
21. Lacorazza HD, Miyazaki Y, Di Cristofano A, Deblasio A, Hedvat C, Zhang J, 
et al. The ETS protein MEF plays a critical role in perforin gene expression 
and the development of natural killer and NK-T  cells. Immunity (2002) 
17(4):437–49. doi:10.1016/S1074-7613(02)00422-3 
22. John SA, Clements JL, Russell LM, Garrett-Sinha LA. Ets-1 regulates 
plasma cell differentiation by interfering with the activity of the transcrip-
tion factor Blimp-1. J Biol Chem (2008) 283(2):951–62. doi:10.1074/jbc.
M705262200 
23. Wang D, John SA, Clements JL, Percy DH, Barton KP, Garrett-Sinha LA. 
Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness 
to TLR9 and autoimmune disease. Int Immunol (2005) 17(9):1179–91. 
doi:10.1093/intimm/dxh295 
24. Russell L, John S, Cullen J, Luo W, Shlomchik MJ, Garrett-Sinha LA. 
Requirement for transcription factor Ets1 in B cell tolerance to self-antigens. 
J Immunol (2015) 195(8):3574–83. doi:10.4049/jimmunol.1500776 
25. Eyquem S, Chemin K, Fasseu M, Chopin M, Sigaux F, Cumano A, et  al. 
The development of early and mature B cells is impaired in mice deficient 
for the Ets-1 transcription factor. Eur J Immunol (2004) 34(11):3187–96. 
doi:10.1002/eji.200425352 
26. Mouly E, Chemin K, Nguyen HV, Chopin M, Mesnard L, Leite-de-Moraes M, 
et al. The Ets-1 transcription factor controls the development and function of 
natural regulatory T cells. J Exp Med (2010) 207(10):2113–25. doi:10.1084/
jem.20092153 
27. Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA. Altered sequence 
of the ETS1 transcription factor may predispose to rheumatoid arthritis 
susceptibility. Scand J Rheumatol (2013) 42(1):11–4. doi:10.3109/03009742.
2012.711367 
28. Yang W, Shen N, Ye DQ, Liu Q, Zhang Y, Qian XX, et  al. Genome-wide 
association study in Asian populations identifies variants in ETS1 and 
WDFY4 associated with systemic lupus erythematosus. PLoS Genet (2010) 
6(2):e1000841. doi:10.1371/journal.pgen.1000841 
29. John S, Russell L, Chin SS, Luo W, Oshima R, Garrett-Sinha LA. Transcription 
factor ets1, but not the closely related factor ets2, inhibits antibody-secret-
ing cell differentiation. Mol Cell Biol (2014) 34(3):522–32. doi:10.1128/
MCB.00612-13 
30. Nikolajczyk BS, Nelsen B, Sen R. Precise alignment of sites required for 
mu enhancer activation in B  cells. Mol Cell Biol (1996) 16(8):4544–54. 
doi:10.1128/MCB.16.8.4544 
31. Nikolajczyk BS, Sanchez JA, Sen R. ETS protein-dependent accessibility 
changes at the immunoglobulin mu heavy chain enhancer. Immunity (1999) 
11(1):11–20. doi:10.1016/S1074-7613(00)80077-1 
32. Jabrane-Ferrat N, Peterlin BM. Ets-1 activates the DRA promoter in B cells. 
Mol Cell Biol (1994) 14(11):7314–21. doi:10.1128/MCB.14.11.7314 
33. Maier H, Colbert J, Fitzsimmons D, Clark DR, Hagman J. Activation of 
the early B-cell-specific mb-1 (Ig-alpha) gene by Pax-5 is dependent on 
an unmethylated Ets binding site. Mol Cell Biol (2003) 23(6):1946–60. 
doi:10.1128/MCB.23.6.1946-1960.2003 
34. Liu H, Grundstrom T. Calcium regulation of GM-CSF by calmodulin-depen-
dent kinase II phosphorylation of Ets1. Mol Biol Cell (2002) 13(12):4497–507. 
doi:10.1091/mbc.E02-03-0149 
35. Roessler S, Gyory I, Imhof S, Spivakov M, Williams RR, Busslinger M, 
et  al. Distinct promoters mediate the regulation of Ebf1 gene expression 
by interleukin-7 and Pax5. Mol Cell Biol (2007) 27(2):579–94. doi:10.1128/
MCB.01192-06 
36. Nguyen HV, Mouly E, Chemin K, Luinaud R, Despres R, Fermand JP, et al. 
The Ets-1 transcription factor is required for Stat1-mediated T-bet expression 
and IgG2a class switching in mouse B cells. Blood (2012) 119(18):4174–81. 
doi:10.1182/blood-2011-09-378182 
37. Liu F, Fan H, Ren D, Dong G, Hu E, Ji J, et al. TLR9-induced miR-155 and 
Ets-1 decrease expression of CD1d on B cells in SLE. Eur J Immunol (2015) 
45(7):1934–45. doi:10.1002/eji.201445286 
38. Barton K, Muthusamy N, Fischer C, Ting CN, Walunas TL, Lanier LL, 
et  al. The Ets-1 transcription factor is required for the development of 
natural killer cells in mice. Immunity (1998) 9(4):555–63. doi:10.1016/
S1074-7613(00)80638-X 
39. Fairfax KA, Corcoran LM, Pridans C, Huntington ND, Kallies A, Nutt SL, et al. 
Different kinetics of blimp-1 induction in B cell subsets revealed by reporter 
gene. J Immunol (2007) 178(7):4104–11. doi:10.4049/jimmunol.178.7.4104 
40. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. Genome-wide analyses 
reveal properties of redundant and specific promoter occupancy within the 
ETS gene family. Genes Dev (2007) 21(15):1882–94. doi:10.1101/gad.1561707 
41. Hollenhorst PC, Ferris MW, Hull MA, Chae H, Kim S, Graves BJ. Oncogenic 
ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes 
Dev (2011) 25(20):2147–57. doi:10.1101/gad.17546311 
42. Plotnik JP, Budka JA, Ferris MW, Hollenhorst PC. ETS1 is a genome-wide 
effector of RAS/ERK signaling in epithelial cells. Nucleic Acids Res (2014) 
42(19):11928–40. doi:10.1093/nar/gku929 
43. Landt SG, Marinov GK, Kundaje A, Kheradpour P, Pauli F, Batzoglou S, 
et al. ChIP-seq guidelines and practices of the ENCODE and modENCODE 
consortia. Genome Res (2012) 22(9):1813–31. doi:10.1101/gr.136184.111 
44. Langmead B. Aligning short sequencing reads with bowtie. Curr Protoc 
Bioinformatics (2010) Chapter 11:Unit 11.7. doi:10.1002/0471250953.
bi1107s32 
45. Feng J, Liu T, Zhang Y. Using MACS to identify peaks from ChIP-seq data. Curr 
Protoc Bioinformatics (2011) Chapter 2:Unit 2.14. doi:10.1002/0471250953.
bi0214s34 
46. Yu G, Wang LG, He QY. ChIPseeker: an R/bioconductor package for ChIP 
peak annotation, comparison and visualization. Bioinformatics (2015) 
31(14):2382–3. doi:10.1093/bioinformatics/btv145 
47. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple com-
binations of lineage-determining transcription factors prime cis-regulatory 
elements required for macrophage and B  cell identities. Mol Cell (2010) 
38(4):576–89. doi:10.1016/j.molcel.2010.05.004 
48. Zambelli F, Pesole G, Pavesi G. PscanChIP: finding over-represented 
transcription factor-binding site motifs and their correlations in sequences 
from ChIP-Seq experiments. Nucleic Acids Res (2013) 41(Web Server 
issue):W535–43. doi:10.1093/nar/gkt448 
49. Stamatoyannopoulos JA, Snyder M, Hardison R, Ren B, Gingeras T, Gilbert 
DM, et  al. An encyclopedia of mouse DNA elements (Mouse ENCODE). 
Genome Biol (2012) 13(8):418. doi:10.1186/gb-2012-13-8-418 
50. Lara-Astiaso D, Weiner A, Lorenzo-Vivas E, Zaretsky I, Jaitin DA, David E, 
et al. Immunogenetics. Chromatin state dynamics during blood formation. 
Science (2014) 345(6199):943–9. doi:10.1126/science.1256271 
51. Revilla IDR, Bilic I, Vilagos B, Tagoh H, Ebert A, Tamir IM, et al. The B-cell 
identity factor Pax5 regulates distinct transcriptional programmes in early 
and late B lymphopoiesis. EMBO J (2012) 31(14):3130–46. doi:10.1038/
emboj.2012.155 
52. Lai WK, Bard JE, Buck MJ. ArchTEx: accurate extraction and visualization 
of next-generation sequence data. Bioinformatics (2012) 28(7):1021–3. 
doi:10.1093/bioinformatics/bts063 
53. Wohner M, Tagoh H, Bilic I, Jaritz M, Poliakova DK, Fischer M, et  al. 
Molecular functions of the transcription factors E2A and E2-2 in controlling 
germinal center B  cell and plasma cell development. J Exp Med (2016) 
213(7):1201–21. doi:10.1084/jem.20152002 
54. Kwon H, Thierry-Mieg D, Thierry-Mieg J, Kim HP, Oh J, Tunyaplin C, et al. 
Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional 
16
Saelee et al. Ets1 Regulates Autoimmune-Associated Genes
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 383
cooperation of STAT3 and IRF4 transcription factors. Immunity (2009) 
31(6):941–52. doi:10.1016/j.immuni.2009.10.008 
55. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential 
gene and transcript expression analysis of RNA-seq experiments with 
TopHat and Cufflinks. Nat Protoc (2012) 7(3):562–78. doi:10.1038/nprot. 
2012.016 
56. Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, et al. DAVID bioin-
formatics resources: expanded annotation database and novel algorithms to 
better extract biology from large gene lists. Nucleic Acids Res (2007) 35(Web 
Server issue):W169–75. doi:10.1093/nar/gkm415 
57. Morinobu A, Gadina M, Strober W, Visconti R, Fornace A, Montagna C, 
et al. STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma 
production but not for cell proliferation. Proc Natl Acad Sci U S A (2002) 
99(19):12281–6. doi:10.1073/pnas.182618999 
58. Negro R, Gobessi S, Longo PG, He Y, Zhang ZY, Laurenti L, et  al. 
Overexpression of the autoimmunity-associated phosphatase PTPN22 
promotes survival of antigen-stimulated CLL cells by selectively activating 
AKT. Blood (2012) 119(26):6278–87. doi:10.1182/blood-2012-01-403162 
59. Chen R, Belanger S, Frederick MA, Li B, Johnston RJ, Xiao N, et  al. In 
vivo RNA interference screens identify regulators of antiviral CD4(+) and 
CD8(+) T cell differentiation. Immunity (2014) 41(2):325–38. doi:10.1016/j.
immuni.2014.08.002 
60. Valentine MA, Czernik AJ, Rachie N, Hidaka H, Fisher CL, Cambier JC, et al. 
Anti-immunoglobulin M activates nuclear calcium/calmodulin-dependent 
protein kinase II in human B lymphocytes. J Exp Med (1995) 182(6):1943–9. 
doi:10.1084/jem.182.6.1943 
61. Cowley DO, Graves BJ. Phosphorylation represses Ets-1 DNA binding by 
reinforcing autoinhibition. Genes Dev (2000) 14(3):366–76. 
62. Medvedovic J, Ebert A, Tagoh H, Busslinger M. Pax5: a master regulator of 
B cell development and leukemogenesis. Adv Immunol (2011) 111:179–206. 
doi:10.1016/B978-0-12-385991-4.00005-2 
63. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of 
B cell identity and function. Nat Immunol (2007) 8(5):463–70. doi:10.1038/
ni1454 
64. Decker T, Pasca di Magliano M, McManus S, Sun Q, Bonifer C, Tagoh H, 
et al. Stepwise activation of enhancer and promoter regions of the B cell com-
mitment gene Pax5 in early lymphopoiesis. Immunity (2009) 30(4):508–20. 
doi:10.1016/j.immuni.2009.01.012 
65. Yue F, Cheng Y, Breschi A, Vierstra J, Wu W, Ryba T, et al. A comparative 
encyclopedia of DNA elements in the mouse genome. Nature (2014) 
515(7527):355–64. doi:10.1038/nature13992 
66. Rosenbloom KR, Dreszer TR, Long JC, Malladi VS, Sloan CA, Raney BJ, 
et al. ENCODE whole-genome data in the UCSC Genome Browser: update 
2012. Nucleic Acids Res (2012) 40(Database issue):D912–7. doi:10.1093/nar/
gkr1012 
67. Bories JC, Willerford DM, Grevin D, Davidson L, Camus A, Martin P, et al. 
Increased T-cell apoptosis and terminal B-cell differentiation induced by 
inactivation of the Ets-1 proto-oncogene. Nature (1995) 377(6550):635–8. 
doi:10.1038/377635a0 
68. Ou Y. Anthrax toxin receptor 2 gene (ANTXR2) rs4333130 is associated with 
ankylosing spondylitis. Int J Clin Exp Med (2015) 8(5):7679–83. 
69. Fischer A, Schmid B, Ellinghaus D, Nothnagel M, Gaede KI, Schurmann M, 
et al. A novel sarcoidosis risk locus for Europeans on chromosome 11q13.1. 
Am J Respir Crit Care Med (2012) 186(9):877–85. doi:10.1164/rccm.201204- 
0708OC 
70. Douglas KB, Windels DC, Zhao J, Gadeliya AV, Wu H, Kaufman KM, 
et  al. Complement receptor 2 polymorphisms associated with systemic 
lupus erythematosus modulate alternative splicing. Genes Immun (2009) 
10(5):457–69. doi:10.1038/gene.2009.27 
71. Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, Choi JY, et  al. Genome-
wide association study identifies GIMAP as a novel susceptibility locus 
for Behcet’s disease. Ann Rheum Dis (2013) 72(9):1510–6. doi:10.1136/
annrheumdis-2011-200288 
72. Farh KK, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, Beik S, et  al. 
Genetic and epigenetic fine mapping of causal autoimmune disease variants. 
Nature (2015) 518(7539):337–43. doi:10.1038/nature13835 
73. Ferreira RC, Freitag DF, Cutler AJ, Howson JM, Rainbow DB, Smyth DJ, 
et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling 
and influences risk of diverse inflammatory diseases. PLoS Genet (2013) 
9(4):e1003444. doi:10.1371/journal.pgen.1003444 
74. Nath SK, Han S, Kim-Howard X, Kelly JA, Viswanathan P, Gilkeson GS, et al. 
A nonsynonymous functional variant in integrin-alpha(M) (encoded by 
ITGAM) is associated with systemic lupus erythematosus. Nat Genet (2008) 
40(2):152–4. doi:10.1038/ng.71 
75. Carmona FD, Simeon CP, Beretta L, Carreira P, Vonk MC, Rios-Fernandez R, 
et al. Association of a non-synonymous functional variant of the ITGAM gene 
with systemic sclerosis. Ann Rheum Dis (2011) 70(11):2050–2. doi:10.1136/
ard.2010.148874 
76. Rahman P, Bartlett S, Siannis F, Pellett FJ, Farewell VT, Peddle L, et  al. 
CARD15: a pleiotropic autoimmune gene that confers susceptibility to pso-
riatic arthritis. Am J Hum Genet (2003) 73(3):677–81. doi:10.1086/378076 
77. Kirino Y, Zhou Q, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. 
Targeted resequencing implicates the familial Mediterranean fever gene 
MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease. Proc Natl 
Acad Sci U S A (2013) 110(20):8134–9. doi:10.1073/pnas.1306352110 
78. Huang CH, Wong RH, Wei JC, Tsay MD, Chen WC, Chen HY, et al. Effects 
of genetic polymorphisms of programmed cell death 1 and its ligands on 
the development of ankylosing spondylitis. Rheumatology (Oxford) (2011) 
50(10):1809–13. doi:10.1093/rheumatology/ker211 
79. Okada Y, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, et al. Meta-analysis 
identifies nine new loci associated with rheumatoid arthritis in the Japanese 
population. Nat Genet (2012) 44(5):511–6. doi:10.1038/ng.2231 
80. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, et  al. A 
large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 
and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009) 
41(11):1228–33. doi:10.1038/ng.468 
81. Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C, 
et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with 
rheumatoid arthritis risk. Nat Genet (2009) 41(12):1313–8. doi:10.1038/
ng.479 
82. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, 
et  al. A functional variant of lymphoid tyrosine phosphatase is associated 
with type I diabetes. Nat Genet (2004) 36(4):337–8. doi:10.1038/ng1323 
83. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, 
Alexander HC, et al. A missense single-nucleotide polymorphism in a gene 
encoding a protein tyrosine phosphatase (PTPN22) is associated with rheu-
matoid arthritis. Am J Hum Genet (2004) 75(2):330–7. doi:10.1086/422827 
84. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, 
et al. Genetic association of the R620W polymorphism of protein tyrosine 
phosphatase PTPN22 with human SLE. Am J Hum Genet (2004) 75(3):504–7. 
doi:10.1086/423790 
85. Carr EJ, Niederer HA, Williams J, Harper L, Watts RA, Lyons PA, 
et  al. Confirmation of the genetic association of CTLA4 and PTPN22 
with ANCA-associated vasculitis. BMC Med Genet (2009) 10:121. 
doi:10.1186/1471-2350-10-121 
86. Bowes J, Loehr S, Budu-Aggrey A, Uebe S, Bruce IN, Feletar M, et  al. 
PTPN22 is associated with susceptibility to psoriatic arthritis but not pso-
riasis: evidence for a further PsA-specific risk locus. Ann Rheum Dis (2015) 
74(10):1882–5. doi:10.1136/annrheumdis-2014-207187 
87. Vandiedonck C, Capdevielle C, Giraud M, Krumeich S, Jais JP, Eymard B, 
et al. Association of the PTPN22*R620W polymorphism with autoimmune 
myasthenia gravis. Ann Neurol (2006) 59(2):404–7. doi:10.1002/ana.20751 
88. Heward JM, Brand OJ, Barrett JC, Carr-Smith JD, Franklyn JA, Gough SC. 
Association of PTPN22 haplotypes with Graves’ disease. J Clin Endocrinol 
Metab (2007) 92(2):685–90. doi:10.1210/jc.2006-2064 
89. Zhao SX, Xue LQ, Liu W, Gu ZH, Pan CM, Yang SY, et al. Robust evidence 
for five new Graves’ disease risk loci from a staged genome-wide association 
analysis. Hum Mol Genet (2013) 22(16):3347–62. doi:10.1093/hmg/ddt183 
90. Hou S, Yang Z, Du L, Jiang Z, Shu Q, Chen Y, et al. Identification of a suscep-
tibility locus in STAT4 for Behcet’s disease in Han Chinese in a genome-wide 
association study. Arthritis Rheum (2012) 64(12):4104–13. doi:10.1002/
art.37708 
91. Zervou MI, Sidiropoulos P, Petraki E, Vazgiourakis V, Krasoudaki E, 
Raptopoulou A, et al. Association of a TRAF1 and a STAT4 gene polymor-
phism with increased risk for rheumatoid arthritis in a genetically homo-
geneous population. Hum Immunol (2008) 69(9):567–71. doi:10.1016/j.
humimm.2008.06.006 
92. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al. 
STAT4 and the risk of rheumatoid arthritis and systemic lupus erythemato-
sus. N Engl J Med (2007) 357(10):977–86. doi:10.1056/NEJMoa073003 
17
Saelee et al. Ets1 Regulates Autoimmune-Associated Genes
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 383
93. Zervou MI, Goulielmos GN, Castro-Giner F, Tosca AD, Krueger-Krasagakis S. 
STAT4 gene polymorphism is associated with psoriasis in the genetically 
homogeneous population of Crete, Greece. Hum Immunol (2009) 70(9):738–
41. doi:10.1016/j.humimm.2009.05.008 
94. Gestermann N, Mekinian A, Comets E, Loiseau P, Puechal X, Hachulla E, 
et al. STAT4 is a confirmed genetic risk factor for Sjogren’s syndrome and 
could be involved in type 1 interferon pathway signaling. Genes Immun 
(2010) 11(5):432–8. doi:10.1038/gene.2010.29 
95. Rueda B, Broen J, Simeon C, Hesselstrand R, Diaz B, Suarez H, et al. The 
STAT4 gene influences the genetic predisposition to systemic sclerosis 
phenotype. Hum Mol Genet (2009) 18(11):2071–7. doi:10.1093/hmg/ddp119 
96. Sun C, Zhi D, Shen S, Luo F, Sanjeevi CB. SNPs in the exons of toll-like recep-
tors are associated with susceptibility to type 1 diabetes in Chinese population. 
Hum Immunol (2014) 75(11):1084–8. doi:10.1016/j.humimm.2014.09.008 
97. Xiao W, Liu Z, Lin J, Li J, Wu K, Ma Y, et al. Polymorphisms in TLR1, TLR6 
and TLR10 genes and the risk of Graves’ disease. Autoimmunity (2015) 
48(1):13–8. doi:10.3109/08916934.2014.939269 
98. Seok H, Suh DW, Jo B, Lee HB, Jang HM, Park HK, et  al. Association 
between TLR1 polymorphisms and alopecia areata. Autoimmunity (2014) 
47(6):372–7. doi:10.3109/08916934.2014.910769 
99. Nishimoto K, Kochi Y, Ikari K, Yamamoto K, Suzuki A, Shimane K, et al. 
Association study of TRAF1-C5 polymorphisms with susceptibility to rheu-
matoid arthritis and systemic lupus erythematosus in Japanese. Ann Rheum 
Dis (2010) 69(2):368–73. doi:10.1136/ard.2008.104315 
100. Redler S, Brockschmidt FF, Forstbauer L, Giehl KA, Herold C, 
Eigelshoven S, et  al. The TRAF1/C5 locus confers risk for familial 
and severe alopecia areata. Br J Dermatol (2010) 162(4):866–9. 
doi:10.1111/j.1365-2133.2009.09598.x 
101. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, et  al. 
Identification of 15 new psoriasis susceptibility loci highlights the role 
of innate immunity. Nat Genet (2012) 44(12):1341–8. doi:10.1038/
ng.2467 
102. Sun Y, Zuo X, Zheng X, Zhou F, Liang B, Liu H, et  al. A comprehensive 
association analysis confirms ZMIZ1 to be a susceptibility gene for vitiligo 
in Chinese population. J Med Genet (2014) 51(5):345–53. doi:10.1136/
jmedgenet-2013-102233 
103. Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, et al. 
Combined analysis of genome-wide association studies for Crohn disease 
and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 
(2012) 90(4):636–47. doi:10.1016/j.ajhg.2012.02.020 
104. Kallies A, Hasbold J, Tarlinton DM, Dietrich W, Corcoran LM, Hodgkin PD, 
et al. Plasma cell ontogeny defined by quantitative changes in blimp-1 expres-
sion. J Exp Med (2004) 200(8):967–77. doi:10.1084/jem.20040973 
105. Solomon LA, Li SK, Piskorz J, Xu LS, DeKoter RP. Genome-wide comparison 
of PU.1 and Spi-B binding sites in a mouse B lymphoma cell line. BMC 
Genomics (2015) 16:76. doi:10.1186/s12864-015-1303-0 
106. Niebuhr B, Kriebitzsch N, Fischer M, Behrens K, Gunther T, Alawi M, et al. 
Runx1 is essential at two stages of early murine B-cell development. Blood 
(2013) 122(3):413–23. doi:10.1182/blood-2013-01-480244 
107. Cheng Y, Ma Z, Kim BH, Wu W, Cayting P, Boyle AP, et  al. Principles of 
regulatory information conservation between mouse and human. Nature 
(2014) 515(7527):371–5. doi:10.1038/nature13985 
108. Hollenhorst PC, Chandler KJ, Poulsen RL, Johnson WE, Speck NA, Graves BJ. 
DNA specificity determinants associate with distinct transcription factor 
functions. PLoS Genet (2009) 5(12):e1000778. doi:10.1371/journal.
pgen.1000778 
109. Carotta S, Willis SN, Hasbold J, Inouye M, Pang SHM, Emslie D, et al. The 
transcription factors IRF8 and PU.1 negatively regulate plasma cell differenti-
ation. J Exp Med (2014) 211(11):2169–81. doi:10.1084/jem.20140425 
110. Liang Y, Pan HF, Ye DQ. Therapeutic potential of STAT4 in autoimmunity. 
Expert Opin Ther Targets (2014) 18(8):945–60. doi:10.1517/14728222.2014.
920325 
111. Rawlings DJ, Dai X, Buckner JH. The role of PTPN22 risk variant in the 
development of autoimmunity: finding common ground between mouse and 
human. J Immunol (2015) 194(7):2977–84. doi:10.4049/jimmunol.1403034 
112. Korman BD, Kastner DL, Gregersen PK, Remmers EF. STAT4: genetics, 
mechanisms, and implications for autoimmunity. Curr Allergy Asthma Rep 
(2008) 8(5):398–403. doi:10.1007/s11882-008-0077-8 
113. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ 
T cell immunity. Nat Rev Immunol (2010) 10(4):236–47. doi:10.1038/nri2729 
114. Raj P, Rai E, Song R, Khan S, Wakeland BE, Viswanathan K, et al. Regulatory 
polymorphisms modulate the expression of HLA class II molecules and 
promote autoimmunity. Elife (2016) 5:e12089. doi:10.7554/eLife.12089 
115. Xu Z, Duan B, Croker BP, Morel L. STAT4 deficiency reduces autoantibody 
production and glomerulonephritis in a mouse model of lupus. Clin Immunol 
(2006) 120(2):189–98. doi:10.1016/j.clim.2006.03.009 
116. Wang Y, Shaked I, Stanford SM, Zhou W, Curtsinger JM, Mikulski Z, et al. The 
autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, 
type 1 interferon-dependent immunity. Immunity (2013) 39(1):111–22. 
doi:10.1016/j.immuni.2013.06.013 
117. Oh YK, Jang E, Paik DJ, Youn J. Early growth response-1 plays a non-re-
dundant role in the differentiation of B cells into plasma cells. Immune Netw 
(2015) 15(3):161–6. doi:10.4110/in.2015.15.3.161 
118. Tsao HW, Tai TS, Tseng W, Chang HH, Grenningloh R, Miaw SC, et al. Ets-1 
facilitates nuclear entry of NFAT proteins and their recruitment to the IL-2 
promoter. Proc Natl Acad Sci U S A (2013) 110(39):15776–81. doi:10.1073/
pnas.1304343110 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Saelee, Kearly, Nutt and Garrett-Sinha. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (CC 
BY). The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
